Search
Immunome Inc
IMNMAdd to Watchlist
22.760USD
-0.320-1.39%
Close 07-31 16:00（ET）Quotes delayed by 15 min
2.58BMarket Cap
LossP/E TTM
Earnings Forecast
Currency: USD Updated: 2026-07-31The current earnings forecast score of Immunome Inc is 8.43, ranking 128 out of 385 in the Biotechnology & Medical Research industry. The average price target is 23.50, with a high of 38.00 and a low of 18.00.
Analyst Rating
Based on
14
analysts
Buy
Current Rating
35.500
Target Price
+55.98%
Upside Space
Strong Buy
Buy
Hold
Sell
Strong Sell
Peer Comparison
496
Total
6
Median
7
Average
Company name
Ratings
Analysts
Immunome Inc
IMNM
14
Beigene Ltd
ONC
28
Ionis Pharmaceuticals Inc
IONS
27
argenx SE
ARGX
26
Kymera Therapeutics Inc
KYMR
24
Insmed Inc
INSM
23
1
2
3
...
99
Support & Resistance
Relevant data have not been disclosed by the company yet.
Financial Forecasting
EPS
Revenue
Net Profit
EBIT
Forecast
Actual
FAQs
What is Immunome Inc's expected revenue for the next quarter?
Immunome Inc's expected revenue is 181.82K.
What is Immunome Inc's price target?
Analysts forecast that Immunome Inc's price target is USD 23.50, with the highest forecast at USD 38.00 and the lowest forecast at USD 18.00.
How have Immunome IncIMNM's recent earnings per share performed?
The market expectation was USD -0.48, while Immunome IncIMNM's earnings per share (EPS) for the previous quarter was USD -0.74. EPS for the next quarter is expected at USD -0.52.
What is the analyst rating for Immunome Inc?
Based on the ratings of Immunome Inc's stock from 14 analysts, most analysts support a Buy trend. After considering the opinions of other analysts, we ultimately rate Apple's stock as Buy. Please note that this is not trading advice. You still need to conduct your own analysis.